BMO Capital Reiterates Buy Rating on ICON PLC with $187 Price Target
BMO Capital reaffirms its buy stance on ICON PLC, setting a price target of $187, a 8.10% upside from the current price.
Key Points
- BMO Capital reiterated its buy rating on ICON PLC (NASDAQ:ICLR) with a price target of $187 as of June 25, 2026.
- BMO Capital's $187 price target implies 8.10% upside from ICON Public Limited Company's ($ICLR) current $172.99 share price.
- ICON PLC's stock traded at $158.17 on Thursday, with a market cap of $10.78 billion and a P/E ratio of 48.36.
- Analysts like RBC Capital and TD Cowen also support ICON with buy ratings, while B of A Securities maintains a sell rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BMO Capital has reiterated its buy rating on ICON Public Limited Company, trading under the ticker ICLR on the NasdaqGS, maintaining a price target of $187. This update came on June 25, 2026, with shares trading around $158.17 on Thursday.
BMO Capital vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
ICON Public Limited Company Stock Up 1.7%
Shares of NasdaqGS:ICLR traded near $158.17 on Thursday. ICON Public Limited Company has a market cap of approximately $10.78 billion and a P/E ratio of 48.36. The stock has seen a 52-week low of $66.57 and a high of $211.00, with a 50-day moving average of $124.49 and a 200-day moving average of $149.71. The company's beta is 1.271, indicating slightly higher volatility compared to the market.
$ICLR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, several analysts weighed in on ICON PLC. BMO Capital maintained its buy rating with a $187 price target. RBC Capital upgraded the stock to a buy, setting a target of $185. TD Cowen also maintained a buy stance with a higher target of $197. Meanwhile, Barclays and JP Morgan held their ratings at hold, with targets of $175 and $155, respectively. B of A Securities stood out by maintaining a sell rating with a target of $150.
Insider Buying and Selling at ICON Public Limited Company
On May 14, 2026, several insiders were active at ICON PLC. Dr. John Climax bought and sold 5,005 shares, while Ronan Martin Murphy and Eugene Pacelli McCague also traded shares in similar amounts. These transactions were not part of any pre-scheduled trading plans.
Other Institutional Activity in ICON PLC
Several institutional investors adjusted their positions in ICON PLC. Artisan Partners Limited Partnership increased its holdings by 1,404,968 shares to a total of 8,278,945 shares, valued at about $916.15 million. Wellington Management Group LLP added 1,562,287 shares, ending with 5,913,037 shares worth approximately $654.34 million. Harris Associates L.P. grew its stake by 1,841,151 shares, reaching 4,351,317 shares valued at $481.52 million. FMR LLC also increased its position by 1,076,111 shares, holding 4,174,006 shares worth $461.90 million. Invesco Ltd. made a smaller addition of 121,973 shares, totaling 3,878,869 shares valued at $429.24 million.
About ICON PLC
ICON Public Limited Company is a healthcare firm based in Dublin, Ireland. It provides outsourced development and commercialization services globally, including clinical trial management and consulting. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. Founded in 1989, ICON is led by CEO Mr. Barry Balfe and employs around 40,100 people worldwide.
Bottom Line
ICON PLC continues to attract positive attention from analysts, with BMO Capital reiterating its buy rating and setting a $187 price target. The stock's performance, trading at $158.17, reflects a solid market presence with a robust 52-week range. Investors and analysts closely monitor such updates as they provide insights into potential future performance, though it's important to remember that analyst ratings are opinions and not guarantees.
Get ICON Public Limited Company alerts
New 13F filings, insider trades, and analyst moves on $ICLR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.